Oca 1,5 mg (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 94 | 原発性硬化性胆管炎 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-002205-38-IT (EUCTR) | 02/12/2015 | 12/02/2018 | A Study of Obeticholic Acid (OCA) in Patients with Primary Sclerosing Cholangitis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled,Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis - AESOP (Assessment of Efficacy and Safety of OCA in PSC) | Primary Sclerosing Cholangitis MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: OCA 1,5 mg Product Code: INT-747, OCA INN or Proposed INN: ACIDO OBETICOLICO Other descriptive name: ACIDO OBETICOLICO Product Name: OCA 5 mg Product Code: INT-747, OCA INN or Proposed INN: ACIDO OBETICOLICO Other descriptive name: ACIDO OBETICOLICO | INTERCEPT PHARMACEUTICALS INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 75 | Phase 2 | United States;Italy |